Alzheimer's Society
Jump to: content Jump to: navigation   Accessibility Contact Us Mobile Shop

Go to Graphical version

 

Comment on Dimebolin (dimebon) increasing Brain Beta Amyloid in Mouse Models

Published 15 July 2009

Dimebolin, originally administered as an antihistamine, has previously been found to help slow the decline of cognitive ability in participants.

This study analysed tau and how dimebolin affects build up of the toxic beta amyloid protein, which is widely believed to be linked to the development of dementia.

This research showed that while dimebolin had a beneficial effect it actually caused an increase of the beta amyloid in mouse models.
'This head scratching research has thrown up surprising results and suggests that while dimebolin provides cognitive benefits it may actually increase levels of toxic beta amyloid in the brain. One possible explanation may be that dimebolin is accelerating the process of beta amyloid development, which may reduce its toxicity.  The questions surrounding whether beta amyloid causes nerve death in Alzheimer's or is a bi-product of the process must be addressed by further research.

'One in three people over 65 will die with dementia. Further, more robust research is needed to clarify whether dimebolin is an effective treatment for Alzheimer's in the long term and if these puzzling increases in beta amyloid are also seen in human brains. With the right investment, dementia can be defeated. Alzheimer's Society funds research to improve the lives of people today and to find a cure for tomorrow.'
Professor Clive Ballard
Director of Research
Alzheimer's Society

Ends

Reference: Samuel Gandy, Dimebon regulates amyloid beta metabolism in cultured cells, isolated nerve terminals and interstitial fluid of living rodent brain.

Notes to editors
  • Alzheimer's Society researchers at ICAD are available for interview or comment on request.
  • The International Conference on Alzheimer's Disease is held in Vienna from 11 - 16 July.  Please visit ICAD for further information.
  • One in three people over 65 will die with dementia
  • Alzheimer's Society research shows that 700,000 people in the UK have a form of dementia, more than half have Alzheimer's disease. In less than 20 years nearly a million people will be living with dementia. This will soar to 1.7 million people by 2051.
  •  Alzheimer's Society champions the rights of people living with dementia and the millions of people who care for them.
  • Alzheimer's Society works in England, Wales and Northern Ireland
  • Alzheimer's Society needs to raise money to help people live well with dementia today and for research to find a cure for tomorrow. You can donate now by calling 0845 306 0898 or visiting alzheimers.org.uk
  • Alzheimer's Society provides a National Dementia Helpline, the number is 0845 300 0336 or visit alzheimers.org.uk
For futher information please visit alzheimers.org.uk/icad or contact the press office on 0207 423 3595 or email press@alzheimers.org.uk